These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33558334)

  • 1. Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
    Henrich IC; Jain K; Young R; Quick L; Lindsay JM; Park DH; Oliveira AM; Blobel GA; Chou MM
    Cancer Res; 2021 Apr; 81(8):2171-2183. PubMed ID: 33558334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma.
    Jain K; Henrich IC; Quick L; Young R; Mondal S; Oliveira AM; Blobel GA; Chou MM
    Cancer Res Commun; 2023 Aug; 3(8):1615-1627. PubMed ID: 37615015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma.
    Henrich IC; Young R; Quick L; Oliveira AM; Chou MM
    Mol Cancer Res; 2018 Dec; 16(12):1834-1843. PubMed ID: 30131449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
    Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
    J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.
    Luo W; Hoang H; Zhu H; Miller K; Mo X; Eguchi S; Tian M; Liao Y; Ayello J; Rosenblum JM; Marcondes M; Currier M; Mardis E; Cripe T; Lee D; Cairo MS
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39266215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immune-related gene signature for determining Ewing sarcoma prognosis based on machine learning.
    Ren EH; Deng YJ; Yuan WH; Wu ZL; Zhang GZ; Xie QQ
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):153-165. PubMed ID: 32968877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.
    Sand LG; Berghuis D; Szuhai K; Hogendoorn PC
    Cancer Immunol Immunother; 2016 Aug; 65(8):995-1002. PubMed ID: 27369431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma.
    Yu L; Deng Y; Wang X; Santos C; Davis IJ; Earp HS; Liu P
    Nat Commun; 2024 Jun; 15(1):5292. PubMed ID: 38906855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Jak1-STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis.
    Quick L; Young R; Henrich IC; Wang X; Asmann YW; Oliveira AM; Chou MM
    Cancer Res; 2016 Sep; 76(18):5337-47. PubMed ID: 27440725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma.
    Krook MA; Nicholls LA; Scannell CA; Chugh R; Thomas DG; Lawlor ER
    Mol Cancer Res; 2014 Jun; 12(6):953-64. PubMed ID: 24651452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
    Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
    Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the tumor microenvironment of Ewing sarcoma.
    Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
    Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously.
    Luo W; Hoang H; Miller KE; Zhu H; Xu S; Mo X; Garfinkle EAR; Costello H; Wijeratne S; Chemnitz W; Gandhi R; Liao Y; Ayello J; Gardenswartz A; Rosenblum JM; Cassady KA; Mardis ER; Lee DA; Cripe TP; Cairo MS
    J Exp Clin Cancer Res; 2024 Jul; 43(1):193. PubMed ID: 38992659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
    Mauldin IS; Wages NA; Stowman AM; Wang E; Smolkin ME; Olson WC; Deacon DH; Smith KT; Galeassi NV; Chianese-Bullock KA; Dengel LT; Marincola FM; Petroni GR; Mullins DW; Slingluff CL
    Cancer Immunol Immunother; 2016 Oct; 65(10):1189-99. PubMed ID: 27522581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
    Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
    Front Immunol; 2021; 12():791206. PubMed ID: 34804076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
    Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
    Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
    Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
    Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immunotherapy strategies for Ewing sarcoma.
    Rossig C
    Immunotherapy; 2014; 6(5):611-21. PubMed ID: 24896629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.